대한뉴팜

Daehan New Pharm Co., Ltd. – Emerging as a Hidden Powerhouse in Pharmaceutical Exports

Achieving 10 billion KRW in finished pharmaceutical exports to over 30 countries worldwide through continuous export-expansion strategies

- High export ratio: 21.5% of total sales

- Continued growth in Russia and CIS markets

- Over 10 additional new products under registration in Cuba and Latin America

In 2012, Daehan New Pharm stood out among mid-sized pharmaceutical companies in Korea by achieving an export-to-sales ratio of 21.5%. Beginning with its first exports to Vietnam and other Southeast Asian markets in 1999, the company received the “5 Million Dollar Export Award” in 2007 and went on to reach 10 billion KRW in exports in 2012. This figure represents a 44% year-on-year increase and includes finished pharmaceutical products—such as anti-obesity lines—exported to over 30 countries including Russia and CIS nations, Vietnam, Pakistan, and Cuba. Riding this strong export momentum, Daehan New Pharm is positioning itself to proactively adapt to shifting market environments such as drug price reductions and new FTA policies.

The company’s rapid export growth stems from a strategic commitment of more than a decade to strengthening its global export capabilities. Expanding into overseas markets has driven internal advancements—such as passing rigorous international audits, improving production processes, and achieving manufacturing standardization—while externally contributing to Korea’s national economic interests.

Daehan New Pharm’s export markets are divided into three major regions: CIS, Southeast Asia, and Latin America.

First, exports to Russia and CIS countries, including emerging markets, continue to grow steadily. In 2012 alone, Daehan New Pharm achieved 1.5 million USD in exports from a single product line. Through close collaboration with Russian partners, the company is working to expand this region into a primary export market targeting over 5 million USD annually.

Second, in Vietnam, one of Korea’s major finished pharmaceutical export destinations, Daehan New Pharm accounted for over 5% of Korea’s total export volume in 2009 with performance exceeding 3 million USD. The company is now optimizing its product portfolio with a focus on profitability and sustainability.

Third, Daehan New Pharm holds a unique position in the Cuban market, being one of the few Korean companies exporting finished pharmaceuticals there. In addition to four currently registered products generating annual sales of USD 500,000–600,000, the company is in the process of registering more than ten new items across Cuba and Latin America. Upon completion, annual export revenue from these regions is expected to exceed USD 1 million.

The know-how and international competitiveness built through human pharmaceuticals are also fueling export expansion in the veterinary medicine sector. Initially limited to markets such as Ethiopia and Japan, the company began expanding into Southeast and South Asia in 2009 and has recently entered new markets by supplying feed additives to Iraq and Taiwan.

With its core principles of focus, specialization, and globalization, Daehan New Pharm continues to expand its global network based on the proven quality, brand recognition, and extensive export expertise acknowledged worldwide. The company aims to solidify its position as a competitive global mid-sized enterprise by targeting niche markets, developing export-oriented strategic products, and pursuing profitability-driven growth.